Orphan Drugs
APAC · 3 shared keywords
APAC Plasma-Derived Therapies Market Industry Trends and Forecast to 2034: Segmented by (Product, Application, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Overview
APAC · 2024–2034 · estimates
Market Dashboard
Values shown here are estimates. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Estimate 2024
$6.42 Bn
Estimated value
Estimate 2025
$6.98 Bn
19% of the global market
Projected 2034
$14.66 Bn 110.1%
Adds $7.68 Bn over 9 forecast years
CAGR 2025–2034
8.6%
Faster than 43% of 180 Pharmaceuticals markets here
Key players
5
- APAC is 19.04% of the global market.
- Among regions, the largest is North America at $19.83 Bn.
- Fastest growing: APAC (this report) at 8.6% a year.
- APAC ranks 3rd of 6 by size among regions.
Market size projection
APACSource: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
Value added each year
$7.68 Bn total, 2026–2034
Year-by-year market size, 2024–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $6.42 Bn | — | — |
| 2025 (base) | $6.98 Bn | +$552.5 Mn | — |
| 2026 (forecast) | $7.58 Bn | +$600.0 Mn | +8.6% |
| 2027 (forecast) | $8.23 Bn | +$651.6 Mn | +17.9% |
| 2028 (forecast) | $8.94 Bn | +$707.6 Mn | +28.1% |
| 2029 (forecast) | $9.70 Bn | +$768.5 Mn | +39.1% |
| 2030 (forecast) | $10.54 Bn | +$834.6 Mn | +51.1% |
| 2031 (forecast) | $11.45 Bn | +$906.4 Mn | +64.1% |
| 2032 (forecast) | $12.43 Bn | +$984.3 Mn | +78.2% |
| 2033 (forecast) | $13.50 Bn | +$1.07 Bn | +93.5% |
| 2034 (forecast) | $14.66 Bn | +$1.16 Bn | +110.1% |
Estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
Same market worldwide
By geography
- Global $36.64 Bn
- North America $19.83 Bn
-
US
$14.53 Bn
- Europe $7.05 Bn
- APAC (this report) $6.98 Bn
-
Canada
$3.12 Bn
-
China
$2.87 Bn
-
Japan
$2.50 Bn
- Latin America $1.85 Bn
-
Germany
$1.49 Bn
- Middle East $1.42 Bn
-
France
$1.07 Bn
-
UK
$1.01 Bn
-
Brazil
$946.0 Mn
-
Italy
$875.8 Mn
-
Ecuador
$761.7 Mn
-
Spain
$723.5 Mn
-
India
$715.7 Mn
- Africa $648.4 Mn
-
Saudi Arabia
$632.0 Mn
-
Mexico
$592.4 Mn
-
Australia
$415.7 Mn
-
Russia
$383.0 Mn
-
New Zealand
$363.3 Mn
-
South Africa
$220.7 Mn
-
UAE
$206.2 Mn
-
Egypt
$92.1 Mn
-
Philippines
$89.0 Mn
-
Malaysia
$65.4 Mn
-
Hong Kong
$54.1 Mn
-
Singapore
$42.8 Mn
-
Thailand
$39.9 Mn
-
Kenya
$23.7 Mn
The APAC Plasma-Derived Therapies Market Analysis Executive Summary
Plasma-derived therapies are medicines made from donated blood plasma, such as immunoglobulins, albumin and clotting factors.
Key segments of the plasma-Derived Therapies market include product (Immunoglobulins, Albumin and Coagulation Factors) and application (Immunology, Hematology and Critical Care).
APAC Plasma-Derived Therapies Market Dynamics
Market Growth Drivers
More surgery and intensive care, rising infection risks, new specialty medicines and the growth of hospital pharmacy services are driving the plasma-Derived Therapies market.
Opportunity
Ready-to-use formulations, biosimilars and supply security programmes give the plasma-Derived Therapies market room to grow.
Market Restraints
Drug shortages, price controls, generic competition and strict hospital budgets hold back the plasma-Derived Therapies market.
Competitive Landscape for Plasma-Derived Therapies Market in APAC
The plasma-Derived Therapies market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
Key Players
Healthcare Policies and Regulatory Landscape for Plasma-Derived Therapies Market in APAC
Policy changes and Reimbursement scenario
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for plasma-Derived Therapies. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in APAC.
Beyond the market numbers
Research, trials and patients
What doctors and scientists are doing in Plasma-Derived Therapies right now, from free public sources.
Latest research 1,017 papers since 2021 (worldwide)
- Cold atmospheric plasma in yeast biotechnology for strain improvement and bioprocess stimulation. World journal of microbiology & biotechnology, 2026
- Development of a novel manufacturing process for highly purified and stable immunoglobulin M with enhanced plasma utilization. Vox sanguinis, 2026
- Plasma-derived hyperhomocysteinemia, PGAM5, and oligomeric α-synuclein as a biomarker panel for idiopathic Parkinson's disease. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology, 2026
- Comparative effects of mesenchymal stem cell- and platelet-rich plasma-derived extracellular vesicles on peripheral nerve regeneration following sciatic nerve crush injury. Journal of molecular histology, 2026
- Comment on: Protection of fundamental human rights by improving patient access to plasma-derived therapies and donor health protection. Vox sanguinis, 2026
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
Public data, with sources
Plasma-Derived Therapies in context
Questions, answered with public data
- How much research is published on Plasma-Derived Therapies?
- PubMed lists 1,017 papers added since January 2021 that match this market, worldwide.[1]
[1] PubMed, Papers added since 1 January 2021 matching this market. Retrieved 12 Nov 2026.
Free data on this topic
From our blog
Patient Support Programmes: Helping Patients Stay on TreatmentWHO says only about half of patients in developed countries take long-term medicines as prescribed. Patient…
Biologic Safety Testing: The Quiet Backbone of Drug MakingEvery vaccine, antibody and cell therapy must be tested for sterility, purity and viruses before it reaches…
Cell-Based Immunotherapy: Promise and PriceThe first CAR-T cell therapy was approved in the US in August 2017. These living drugs can work when other…